VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
LearnAll lessons
Candlestick Patterns44 candles, each on two real charts
Pattern GuidesThe playbooks' setups on real breakouts
GlossaryInvesting terms in plain English
MinerviniVCP SetupsTrend Template
O'NeilCup with HandleFlat BaseDouble BottomCANSLIM Leaders
QullamaggieHigh Tight FlagsFlag BreakoutsEpisodic PivotsMomentum Leaders
KellWedge PopEMA Crossback
LivermorePivotal Points
PatternsFalling Wedge & ChannelBase Breakouts
View All Playbooks...
BreakoutsScanner
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
BreakoutsScanner
WatchlistPricing
Ctrl K
Pricing
DNTH
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Scanner
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsScannerWatchlist
DNTHDianthus Therapeutics, Inc.
$83.98$3.5B
Overview & Tools
OverviewChart Terminal ↗Visualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
HomeStocksDNTHCash Flow

Dianthus Therapeutics, Inc. (DNTH) Cash Flow Statement

10Y historyFree accessUpdated daily

Operating cash flow of -$50.3M in 2026Q3 tracked net losses closely (OCF/NI near 1.08), with CapEx below 0.1% of revenue and no dividends or buybacks, indicating cash consumption is driven almost entirely by clinical operations.

Income StatementBalance SheetCash FlowRatios

DNTH Cash Flow Statement

Annual statement

DNTH Cash Flow Statement

Dianthus Therapeutics, Inc. (DNTH) cash flow statement — 10-year operating, investing & financing cash flows

AnnualQuarterly
MetricTTMDec'25Dec'24Dec'23Dec'22Dec'21Dec'20Dec'19Dec'18Dec'17Dec'16
Cash from Operations-175.15M-129.06M-78.18M-36.86M-29.07M-59.53M-64.02M-57.1M-41.89M-22.26M-6.53M
Operating CF Margin %--6338.9%-1253.89%-1304.35%-453.02%-4033.27%-----
Operating CF Growth %-245.38%-65.08%-112.09%-26.8%51.17%7.02%-12.12%-36.33%-88.14%-240.99%-
Net Income-39.79M-162.34M-84.97M-43.55M-28.48M-71.14M-74.94M-76.77M-57.52M-35.49M-9.43M
Depreciation & Amortization317K428K412K355K147K2.02M1.98M1.84M875K376K6K
Stock-Based Compensation41.2M22.79M12.89M2.9M1.52M00002.26M662K
Deferred Taxes000-661K00-12.95M-13.54M000
Other Non-Cash Items-8.62M-6.67M-6.17M-762K-606K11.11M23.07M22.53M10.02M13.41M306K
Working Capital Changes-5.93M16.73M-351K4.86M-1.65M-1.53M-1.19M8.83M3.98M1.32M1.6M
Change in Receivables4.42M755K05.16M-4.16M000000
Change in Inventory00000000000
Change in Payables691K11.28M8.19M661K2.28M-720K948K145K2.5M-1.13M1.01M
Cash from Investing-687.16M-122.83M-286.81M20.25M-59.82M43.43M-10.63M1.53M-91.7M-2.2M-139K
Capital Expenditures-697K-213K-105K-110K-139K-1.26M-400K-3.06M-7.67M-2.2M-139K
CapEx % of Revenue25.64%10.46%1.68%3.89%2.17%85.64%-----
Acquisitions0000000012K00
Investments-----------
Other Investing0000000012K-135K0
Cash from Financing862.15M280.13M255.62M133.57M96.68M89.6M67.74M62.3M142.15M71.49M10.71M
Debt Issued (Net)00000000006.5M
Equity Issued (Net)-102.64M280.13M269.2M72M100M89.6M67.74M62.3M142.15M71.49M4.21M
Dividends Paid00000000000
Share Repurchases317K0000000-88K-213K-107K
Other Financing964.78M0-13.57M61.57M-3.32M000000
Net Change in Cash-169K28.23M-109.37M116.97M7.79M73.5M-6.92M6.73M6.78M47.02M4.04M
Free Cash Flow-175.85M-129.27M-78.28M-36.97M-29.21M-60.8M-64.42M-60.16M-49.56M-24.46M-6.67M
FCF Margin %-6469.87%-6349.36%-1255.57%-1308.24%-455.18%-4118.9%-----
FCF Growth %-60.41%-65.13%-111.75%-26.57%51.95%5.63%-7.08%-21.4%-102.59%-266.86%-
FCF per Share-3.07-3.42-2.35-7.17-7.79-17.70-23.47-26.01-23.80-11.07-3.02
FCF Conversion (FCF/Net Income)4.42x0.80x0.92x0.85x1.02x4.54x0.85x0.74x0.73x0.63x0.69x
Interest Paid00000000000
Taxes Paid00000000000

Key Metrics

Growth RegimeContracting
ProfitabilityNegative
Balance SheetVulnerable
Cash FlowBurning
Top Statement Risk

Cash runway shortfall and dilution

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2026Q3)

Operating Cash Burn Tracks Losses Closely

According to reported quarterly figures, DNTH's operating cash flow has tracked net losses closely, with the OCF-to-net-income ratio near 0.7 to 1.1 across most recent quarters, indicating losses are largely cash-driven rather than accrual-driven.

The ratio of operating cash flow to net income sits near 1.0 in most quarters, which suggests the reported losses are substantially real cash outflows rather than non-cash charges. The 2025Q4 net income of $97.9M against operating cash flow of -$47.0M, however, produces a negative ratio that appears to reflect a large non-operating gain unrelated to core clinical spending. Investors should treat that single quarter as an earnings-quality anomaly rather than evidence of improving conversion.

Free Cash Flow Deeply Negative and Accelerating

Based on reported figures, DNTH's free cash flow deteriorated to -$50.7M in 2026Q3, with FCF margins sitting between -42% and -166% across recent quarters against a tiny legacy revenue base.

Because revenue has largely wound down, FCF margins are mathematically extreme and carry limited analytical meaning beyond confirming the absence of a self-funding business model. The absolute quarterly burn has roughly doubled from around $14.5M in 2024Q2 to over $50M in the latest two quarters, which suggests spending is scaling faster than any income base. The trajectory points toward a rapidly shortening runway rather than a stabilizing cost structure.

Minimal Capital Intensity Confirms Asset-Light Model

As reported in cash flow statements, DNTH's capital expenditures remained negligible, with CapEx below 0.1% of revenue in most quarters and at most $368K in 2026Q3, consistent with outsourced clinical development.

The low capital expenditure profile is consistent with a company that relies on contract research organizations and manufacturing partners rather than owned infrastructure. Capex is therefore not a meaningful use of cash, and nearly the entire burn reflects operating spending on clinical programs. This structure reduces fixed-asset risk but increases dependence on external vendors and trial timelines.

Cash Consumed Entirely by Clinical Operations

Per the reported cash flow data, DNTH paid no dividends and recorded no meaningful buybacks, with the only cash deployment directed at operating activities that consumed roughly $50M per quarter in recent periods.

The absence of dividends and repurchases is appropriate for a clinical-stage entity with negative free cash flow, and it means the full burn is directed toward pipeline development. There is no evidence in the supplied data of acquisitions or debt paydown absorbing capital. The implication is that every dollar of the reported $51 million cash balance is effectively committed to clinical execution, leaving little buffer against trial delays or cost overruns.

Cash Runway Constraint Warrants Monitoring

Based on reported figures, DNTH's roughly $51M cash balance against a quarterly operating burn near $50M suggests a runway potentially under one year, which may indicate a near-term financing event is likely.

If quarterly burn persists near the latest $50M level, the reported cash position would be exhausted within roughly one quarter, a conclusion that is sensitive to the completeness of the cash figure and any undisclosed committed funding, which the supplied data does not confirm. Investors should monitor for a capital raise or partnership announcement, as dilution appears the most probable near-term outcome. Any unreported financing access or cost reduction would materially change this inference, and the absence of forward guidance in the latest report limits confidence in the timing.

DNTH — Frequently Asked Questions

Quick answers to the most common questions about buying DNTH stock.

How much cash does Dianthus Therapeutics, Inc. (DNTH) generate from operations?

Dianthus Therapeutics, Inc. (DNTH) generated $-129.1M in net cash from operating activities in 2025. This reflects the cash generated directly from core business operations.

What is Dianthus Therapeutics, Inc.'s free cash flow?

Dianthus Therapeutics, Inc. (DNTH) reported negative free cash flow of $129.3M in 2025, indicating capital requirements exceeded cash from operations.

What is Dianthus Therapeutics, Inc.'s capital expenditure (CapEx)?

Dianthus Therapeutics, Inc. (DNTH) spent $0.2M on capital expenditures in 2025. CapEx represents the cash invested in physical assets like property, plant, and equipment to maintain or grow the business.